NewsNovo
A formal securities investigation into Larimar Therapeutics, Inc. (NASDAQ: LRMR) is now underway. Pomerantz LLP announced on July 9, 2026 that it is examining claims on behalf of the company's investors.
The specific nature of those claims has not been disclosed. What the announcement establishes The firm's notice, issued from New York, advised Larimar investors to contact Danielle Peyton directly.
Pomerantz provided both an email address (newaction@pomlaw.com) and a direct phone line (646-581-9980, ext. That outreach detail is telling.
It suggests the firm is in active intake mode, seeking to connect with shareholders before any formal complaint is filed.
Keep reading